Cholesterol verlaging (om cardiovasculair risico te verlagen)
|
|
- Benedict Wade
- 6 years ago
- Views:
Transcription
1 Cholesterol verlaging (om cardiovasculair risico te verlagen) Toen, nu en straks Erik Stroes AMC, The Netherlands
2 Outline Cholesterol verlaging: toen, nu en straks Cholesterol verlaging toen Fire and Forget Statins only Cholesterol verlaging nu Cholesterol verlaging toekomst
3 The central role of arterial retention of apob-containing lipoproteins in the pathogenesis of atherosclerosis Boren J, Williams KJ. Curr Opin Lipidol 2016;27:473 83
4 Causative, excacerbating factors vs bystanders Boren, Cur Op Lip 2016
5 ACC/AHA Guidelines Recommend Lowering LDL-C to Reduce the Risk of a CVD Event Patients >21 yr of age without heart failure or ESRD Screen for ASCVD risk factors Measure LDL-C Clinical ASCVD Diabetes mellitus (type 1 or 2) and age of yr and LDL-C mg/dl No diabetes mellitus and age of yr and LDL-C mg/dl LDL-C 190 mg/dl Calculate 10-year risk* of ASCVD Calculate 10-year risk* of ASCVD High-intensity statin therapy If risk <7.5%*, moderateintensity statin therapy If risk 7.5%*, high-intensity statin therapy If risk 7.5, moderate-to-highintensity statin therapy High-intensity statin therapy 2013 ACC/AHA guidelines state that reduction of CVD events according to risk should be achieved with statin treatment in 4 groups with increased CV risk ACC=American College of Cardiologists; AHA=American Heart Association; ASCVD= atherosclerotic cardiovascular disease; ESRD=end-stage renal disease; LDL-C=low-density lipoprotein cholesterol; RCT=randomized controlled trials. Goff et al, JACC 2013 epub Nov 12.; Stone et al. JACC 2014; 63: ; Keaney et al. NEJM 2013; epub Nov 27.
6 LDL-C Lowering Therapies Reduce CV-Risk 2013 ACC/AHA guidelines state that lowering LDL-C lowers ASCVD risk, but since no RCTs have been done to specifically treat to goals, an optimal goal is not supported 2013 ACC/AHA guidelines do not routinely allow for non-statin therapy to treat high-risk patients who: Have a less-than-anticipated response to statins Are unable to tolerate a less-than-recommended intensity of a statin Are completely statin intolerant ACC=American College of Cardiologists; AHA=American Heart Association; ASCVD= atherosclerotic cardiovascular disease; HDL-C=high-density lipoprotein cholesterol; LDL-C=low-density lipoprotein cholesterol; RCT=randomized controlled trials. Stone et al. JACC 2014; 63: ; Keaney et al. NEJM 2013; epub Nov 27
7 Outline Cholesterol verlaging: toen, nu en straks Cholesterol verlaging toen Fire and Forget Statins only Cholesterol verlaging nu Van LDL-c target naar LDL-c eradicatie Van statines naar combinatie therapie Cholesterol verlaging toekomst Low-frequency injectables Tailored therapy
8 Proportional reduction in CHD risk (log scale) Genetic versus Pharmacologic LDLc decrease From LDL-c concentration to life-long LDL-c exposure 30% 20% Ference BA, et al. J Am Coll Cardiol 2015;65: x 2 Factorial Mendelian Randomisation Study Genetically lower LDL-C NPC1L1 LDL-C score HMGCR LDL-C score LDLR rs LDLR 10% ABCG5/8PCSK9 46L rs rs Combined rs NPC1L1 & HMGCR rs12916 HMGCR HMGCR LDL-C LDL-C score score NPC1L1 rs NPC1L1 LDL-C score A to Z GISSI- P SEARCH Lower LDL-C (mg/dl) Pharmacologically lower LDL-C IMPROVE-IT 69.5% reduction in CHD risk for each 1mmol/L (38.6mg/dL) lower LDL-C ALLHAT-LLT ~20% reduction in CHD risk for each 1mmol/L (38.6mg/dL) lower LDL-C
9 Concept change I: Start Early Less LDL-exposure years leads to prevention of disease formation Development of early atherosclerotic vascular disease in familial hypercholesterolaemia showing the potential impact of early recognition and treatment on evolution of the condition Wiegman et al. European Heart Journal doi: /eurheartj/ehv157
10 Proportional Reduction in Event Rate (SE) Concept change II: use combination therapy Ezetimibe induced LDL-c lowering reduces CV-risk 50% 40% 30% 20% CTT-meta-analysis 10% 0% IMPROVE-IT Reduction in LDL-C (mmol/l) CTTC. Lancet 2005;366: CTTC. Lancet 2010;376: Cannon et al. N Engl J Med 2015;372:
11 PCSK9-antibody on top of statins Fourier study 27,564 high-risk, stable patients with established CV disease (prior MI, prior stroke, or symptomatic PAD) Screening, Lipid Stabilization, and Placebo Run-in High or moderate intensity statin therapy (± ezetimibe) LDL-C 70 mg/dl or non-hdl-c 100 mg/dl Evolocumab SC 140 mg Q2W or 420 mg QM RANDOMIZED DOUBLE BLIND Placebo SC Q2W or QM Sabatine MS et al. Am Heart J 2016;173: Follow-up Q 12 weeks 10
12 LDL-C (mm) KM Rate (%) at 3 Years LDL-c reduction and CV-benefit LDL-C by 59% (from 2.4 -> 0.8 [0.5, 1.2] mm) CV outcomes in patients already on statin therapy Evolocumab was safe and well-tolerated 2,5 2,0 1,5 1,0 Placebo 59% mean decline P< Absolute 1.45 mm ( ) HR 0.85 ( ) P< ,6 12,6 Placebo Evolocumab HR 0.80 ( ) P< ,9 7,9 0,5 0,0 Evolocumab Median 0.78 mm IQR [ ] Weeks after randomization Sabatine MS et al. New Engl J Med 2017;376: CV death, MI, stroke, UA, cor revasc CV death, MI, stroke
13 CV-benefit dependent upon LDL-c reduction Independent from pathway Hazard Ratio (95% CI) per 1 mmol/l reduction in LDL-C Median follow-up of 2.2 years in FOURIER vs. 4.9 years on average in CTTC meta-analysis Supplement to Sabatine, et al. N Engl J Med 2017; March 17: online 12 CTTC data from Lancet 2010;376:
14 Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions Weighted Between-Group Difference in Achieved Low-Density Lipoprotein Cholesterol (LDL-C) Level and Relative Risk for Major Vascular Events for Each Class of Intervention MG Silverman et al - JAMA. 2016;316(12): The RR for major vascular events per 1- mmol/l reduction in LDL-C was: 0.77 (95%CI, ; P <.001) for statins 0.75 (95%CI, ; P =.002) for established non-statin interventions that work primarily via up-regulation of LDL receptor expression (ie, diet, bile acid sequestrants, ileal bypass, and ezetimibe) 0.61 (95%CI, ) for PCSK9i (P =.25). The use of statin and non-statin therapies that act via up-regulation of LDL receptor expression to reduce LDL-C were associated with similar RRs of major vascular events per change in LDL-C.
15 CETPi + HMG-CoA SNPs: LDL-c less predictive than apob due to discordance 21 genetic variants with naturally occurring discordance between LDL-C and apob similar in magnitude to what occurs when CETP & HMGCR inhibition are combined Odds Ratio Ference, JAMA 2017 aug.
16 Concept change III: Treat (much more) aggressive From threshold to eradication Achieved on-trial LDL-C concentration, mg/dl (mmol/l) < 50 (< 1.29) (n = 4375) 50 < 75 (1.29 < 1.94) (n = 10,395) 75 < 100 (1.94 < 2.58) (n = 10,091) 100 < 125 (2.58 < 3.23) (n = 8953) 125 < <3.88 (n = 3128) 150 < 175 (3.88 < 4.52) (n = 836) 175 ( 4.52) (n = 375) Major CV events Unadjusted HR (95% CI) Adjusted HR (95% CI)* 194 (4.4) 0.20 ( ) 0.44 ( ) 1185 (11.4) 0.40 ( ) 0.51 ( ) 1664 (16.5) 0.50 ( ) 0.56 ( ) 1480 (16.5) 0.48 ( ) 0.58 ( ) 557 (17.8) 0.51 ( ) 0.64 ( ) 184 (22.0) 0.64 ( ) 0.71 ( ) 123 (32.8) 1.00 (ref) 1.00 (ref) Major coronary events Unadjusted HR (95% CI) Adjusted HR (95% CI)* 129 (2.9) 0.15 ( ) 0.47 ( ) 918 (8.8) 0.36 ( ) 0.53 ( ) 1431 (14.2) 0.50 ( ) 0.58 ( ) 1336 (14.9) 0.51 ( ) 0.62 ( ) 492 (15.7) 0.53 ( ) 0.67 ( ) 170 (20.3) 0.69 ( ) 0.78 ( ) 107 (28.5) 1.00 (ref) 1.00 (ref) Major cerebrovascular events Unadjusted HR (95% CI) Adjusted HR (95% CI)* 72 (1.6) 0.47 ( ) 0.36 ( ) 315 (3.0) 0.62 ( ) 0.46 ( ) 302 (3.0) 0.52 ( ) 0.49 ( ) 205 (2.3) 0.38 ( ) 0.45 ( ) 91 (2.9) 0.47 ( ) 0.58 ( ) 21 (2.5) 0.41 ( ) 0.43 ( ) 23 (6.1) 1.00 (ref) 1.00 (ref) Data taken from 8 randomized statin trials. Values are n (%) unless otherwise indicated. The highest LDL-C category was used as the reference category. *Adjusted for sex, age, smoking status, presence of diabetes mellitus, systolic blood pressure, HDL-C concentration and trial. HDL-C, high-density lipoprotein cholesterol; Boekholdt SM, et al. J Am Coll Cardiol 2014;64:
17 Very low LDL-c levels achieved beyond any target defined in guidelines Achieved LDL-C in mm at 4 Weeks At Randomization <0.5 (N=2669) (N=8003) (N=3444) (N=7471) >2.6 (N=4395) Median Lipid values LDL-C, mm Total cholesterol, mm Triglycerides, mm HDL-C, mm Lipoprotein (a), nm High potency statin, % (> Atorvastatin 40 mg/d) Ezetimibe, % Giugliano RP, Lancet 2017
18 Progressive CV-risk reduction with very-low LDLc achieved CV Death, MI, or Stroke LDL-C (mm) Adj HR (95% CI) < ( ) ( ) P = ( ) ( ) > 2.6 referent Giugliano RP, Lancet 2017 LDL-C (mm) at 4 weeks
19 Exploratory Analysis Pts with LDL-C <0.26 mm at 4 wks N=504: Median [IQR] LDL-C 0.18 [ ] mm = 7 [5-9] mg/dl Cardiovascular Efficacy Safety HR 0.69 ( ) P= ,9 7,3 7,8 2.6 mm <0.26 mm HR 0.59 ( ) P=0.02 4, HR 0.94 ( ) P= ,3 22,8 2.6 mm <0.26 mm HR 1.08 ( ) P= ,4 3,4 0 CVD, MI, Stroke, UA, Cor Revasc CVD, MI, Stroke 0 Serious adverse event AE -> drug discontinued Giugliano RP, Lancet 2017
20 Caveat for combining: cost-efficacy Determined by absolute CV-risk and [LDL-c] >30% 10-year ASCVD risk Clinical ASCVD + diabetes Clinical ASCVD + chronic kidney disease Recent acute coronary syndrome (<3 months) Clinical ASCVD with multiple recurrent events* Percent LDL-C reduction Add ezetimibe Combination therapy PCK9 mab PCSK9 mab maximum dose Initial LDL-C 20% 35% 50% 65% 190 mg/dl mg/dl mg/dl mg/dl mg/dl Possible NNTs with PCKS9i for the recommended populations from the ESC/EAS consensus statement (PCSK9i recommended by the ESC/EAS for rapid progression of ASCVD and LDL-C>100 mg/dl on maximally tolerated efficacious statin and ezetimibe) Robinson JG et al. JACC
21 Outline Cholesterol verlaging: toen, nu en straks Cholesterol verlaging toen Fire and Forget Statins only Cholesterol verlaging nu Van LDL-c target naar LDL-c eradicatie Van statines naar combinatie therapie, Cholesterol verlaging toekomst
22 Opportunities and Challenges for the future LDL-c: Improving adherance Other lipid moieties Lp(a) Remnant cholesterol Personalized medicine Cantos / COMPASS / FOURIER
23 Chowdhury et al., EHJ 2013;34: Relative Risk of Death for Adherence > 80% versus < 80% Meta-analysis of 44 studies, n= ; CVD events; cases of all-cause mortality 9% of all CVD events in Europe could be attributed to poor adherence to vascular medications alone
24 Novel therapeutic modalities: RNAi is an intrinsic process for inhibiting mrna Synthetic sirna dsrna Targeted gene silencing RISC dicer Cleavage Strand separation Complementary pairing mrna Natural process of RNA interference mrna degradation Cleavage
25 Mean percent change (±95% CI) Single dose results in > 3 months 50% LDL-c lowering P-value for all comparisons to placebo < End of study if LDL-C back to baseline Placebo 200 mg 300 mg 500 mg Days from first injection Ray KK, N Engl J Med 2017
26 Mean percent change (±95% CI) Future: twice a year injection = whole year >50 LDLc reduction P-value for all comparisons to placebo < End of study if LDL-C back to baseline Placebo 100 mg 200 mg 300 mg Days from first injection Ray KK, N Engl J Med 2017
27 Opportunities and Challenges for the future LDL-c: Improving adherance Other lipid moieties Lp(a) Remnant cholesterol Personalized medicine Cantos / COMPASS / FOURIER
28 Lp(a) is a causal factor in atherogenesis
29 Lp(a) (q4 vs q1) and Residual CV-Risk in Primary and Secondary prevention Tsimikas Curr Opin Endocrinol Diabetes Obes 2016;23: Q4 LDL-C: AIM-HIGH 54, JUPITER 62 and LIPID 112 mg/dl Q4 of Lp(a): mg/dl
30 Novel therapeutic options in Lp(a) patients Antisense for apo(a) Prakash TP, Nucleic Acids Res 2014
31 Reduction in Lp(a) and OxPL following 2nd generation apo(a)-antisense Viney, Stroes, Tsimikas S, Lancet 2016 Injection site reactions: >80 %
32 Effect of gal-nac apo(a) antisense of Lp(a) *** *** *** * * *** * *** *** *** *** *** Weekly dose ED 50 of 3.9 mg (0.05 ml) Viney, Stroes, Tsimikas, Lancet 2016 Injection site reactions: 0 %
33 Varbo JACC 2013 Remnant cholesterol causally related to CVD-risk Mendelian Randomisation studies
34 Remnant cholesterol is next on the list Apo-CIII antisense potently reduces TG levels and remant chol. Gaudet et al. NEJM 2015
35 Opportunities and Challenges for the future LDL-c: Improving adherance Other lipid moieties Lp(a) Remnant cholesterol Personalized medicine CANTOS / COMPASS / FOURIER
36 The need for Personalized medicine Multiple effective therapeutic regimens Differential benefits within target population
37 Benefit of anti-inflammatory intervention Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10, Countries April June Primary Events Randomized Canakinumab 50 mg SC q 3 months Randomized Canakinumab 150 mg SC q 3 months Randomized Canakinumab 300 mg SC q 3 months* Randomized Placebo SC q 3 months Primary CV Endpoint: Nonfatal MI, Nonfatal Stroke, Cardiovascular Death (MACE) Key Secondary CV Endpoint: MACE + Unstable Angina Requiring Unplanned Revascularization (MACE+) Critical Non-Cardiovascular Safety Endpoints: Cancer and Cancer Mortality, Infection and Infection Mortality Ridker N Engl J Med 2017
38 Cumulative Cumulative Incidence Incidence (%) IL1 beta antibodies MACE reduce CV-MACE (CANTOS) Placebo 150/300mg Placebo SC q 3 months Canakinumab 150/300 SC q 3 months HR %CI P = % reduction in hscrp No change in LDLC 15% reduction in MACE Differential benefits: > median CRP reduction? HR Follow-up Years Ridker PM et al, NEJM 2017
39 CANTOS: Additional Outcomes (per 100 person years of exposure) Adverse Event Placebo (N=3347) Canakinumab SC q 3 months 50 mg (N=2170) 150 mg (N=2284) 300 mg (N=2263) P-trend Any SAE Leukopenia Any infection Fatal infection /0.02* Injection site reaction Any Malignancy Fatal Malignancy Arthritis Osteoarthritis Gout ALT > 3x normal Ridker N Enlg J Med 2017
40 Eikelboom J, N Engl J Med 2017 Rivaroxaban reduces CV-risk in patients with stable CV-disease (COMPASS)
41 At the expense of higher bleeding rate (COMPASS) Eikelboom J, N Engl J Med 2017
42 Landrey M, N Engl J Med 2017 Effects of CETPi (anacetrapib) on lipids
43 Landrey M, N Engl J Med 2017 Anacetrapib (CETPi) decreases CV-risk in stable CVD patients (REVEAL)
44 Proportional reduction in CHD/MI vs absolute reduction in non-hdl c Landrey M, N Engl J Med 2017; Ference B, JAMA 2017.
45 Future CV-treatment: Personalized algorithms High CV-risk High Intensity Statin Residual Lipid Risk Residual Inflamm Risk Residual Thromb. Risk Application of a readily LDL 70 applicable mg/dl (1.8 mmol/l) marker of benefit/harm : LDL 92 mg/dl (2.4 mmol/l) Prior to initiating personalized therapy LDL 130 mg/dl (3.3 mmol/l) CRP 1.8 mg/l CRP 3.8 mg/l CRP 1.9 mg/l Further lipid modulation Ezetimibe 6% RRR PCSK9-ab: (15-) 30% RRR CETPi: 9% RRR Inflammation Reduction IL1B-ab: (15-) 27% RRR Coagulation Reduction Rivaroxa: 24% RRR
46 Nahrendorf, Stroes, et al J Am Coll Cardiol 2015;65(15) Ganz, P. et al..jama 2016;315: Future selection for personalized medicine: Most effective drug for most suitable patient Multimodal imaging: Active pathway analysis using proteomics
47 Opportunities and Challenges for the future LDL-c: Improving adherance Other lipid moieties Lp(a) Remnant cholesterol Personalized medicine CANTOS / COMPASS / FOURIER
48 AMC: John Kastelein Bert Groen Kees Hovingh Max Nieuwdorp Europe: Alberico Catapano Wolfgang Koenig Borge Nordestgaard Acknowledgements US: Matthias Nahrendorf Sam Tsimikas Zahi Fayad PhDs: Renate Hoogeveen Lotte Stiekema Rens Reeskamp Rutger Verbeek Fleur vd Valk Simone Verweij Funding: HORIZON2020 REPROGRAM; CVON-GENIUS; FP7-Nano-Athero; FP7-TRANSCARD
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10,061 39 Countries April 2011 - June 2017
More informationClinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial
Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial RP Giugliano, TR Pedersen, AC Keech, PS Sever, JG Park, and MS Sabatine,
More informationFOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations?
FOURIER: Enough Evidence to Justify Widespread Use? Did It fulfill Its Expectations? CVCT Washington, DC November 3, 2017 Marc S. Sabatine, MD, MPH Chairman, TIMI Study Group Lewis Dexter, MD, Distinguished
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationConsiderations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical
More informationLp(a) Ready for prime time? E Stroes AMC
Lp(a) Ready for prime time? E Stroes AMC Case Male, 45 years old Hypertension: DM: Smoking: Dyslipidemia: Fam history: brother MI (55yr) Lipoprotein(a): 1240 mg/l!!! Lipoprotein(a) = LDL + apo(a) tail
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationWorkshop. Todd Anderson MD / Jacques Genest MD
Workshop Todd Anderson MD / Jacques Genest MD Game-Changing Trials 2017 FOURIER Evolocumab n=27,564 HR 0.80 CANTOS Canakinumab n=10,061 HR 0.85 COMPASS Rivaroxaban + ASA n=27,395 HR 0.76 Key Secondary
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationEffect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes
Effect of the PCSK9 Inhibitor Evolocumab on Cardiovascular Outcomes MS Sabatine, RP Giugliano, SD Wiviott, FJ Raal, CM Ballantyne, R Somaratne, J Legg, SM Wasserman, R Scott, MJ Koren, and EA Stein for
More informationParadim Shift in cholesterol behandeling: van LDL-C target naar LDL-C eradicatie
Paradim Shift in cholesterol behandeling: van LDL-C target naar LDL-C eradicatie Prof. G.Kees Hovingh, MD PhD MBA Dept. Vascular Medicine Academic Medical Center Amsterdam, the Netherlands Risk and profit
More informationReducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
New York City Cardiovascular Symposium December 10, 2017 Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Paul M Ridker, MD, MPH
More informationLipids: new drugs, new trials, new guidelines
Lipids: new drugs, new trials, new guidelines Milan Gupta, MD, FRCPC, FCCS State of the Heart Co-Chair Associate Clinical Professor of Medicine, McMaster University Assistant Professor of Medicine, University
More informationNew Strategies for Lowering LDL - Are They Really Worth It?
New Strategies for Lowering LDL - Are They Really Worth It? Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Eliot Corday Professor of CV Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director,
More informationLandmesser U et al. Eur Heart J 2017; https://doi.org/ /eurheartj/ehx549
2017 Update of ESC/EAS Task Force on Practical Clinical Guidance for PCSK9 inhibition in Patients with Atherosclerotic Cardiovascular Disease or in Familial Hypercholesterolaemia Cardiovascular Outcomes
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More informationMS Sabatine, RP Giugliano, AC Keech, PS Sever, SA Murphy and TR Pedersen, for the FOURIER Steering Committee & Investigators
Evolocumab Reduces Cardiovascular Events in Patients with Baseline LDL-C
More informationMaking War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman
Making War on Cholesterol with New Weapons: How Low Can We/Should We Go? Shaun Goodman Disclosures Research grant support, speaker/consulting honoraria: Sanofi and Regeneron Including ODYSSEY Outcomes
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationCholesterol; what are the future lipid targets?
Cholesterol; what are the future lipid targets? lipidologist out-of-business in 5-10 years? G.Kees Hovingh dept of vascular medicine, Academic Medical Center g.k.hovingh@amc.uva.nl Disclosure - Consultant
More informationTHE ESC/EAS LIPID GUIDELINES IN THE ELDERLY
THE ESC/EAS LIPID GUIDELINES IN THE ELDERLY Alberico L. Catapano alberico.catapano@unimi.it Alberico L. Catapano Potential Conflict Of Interest Prof. Catapano has received honoraria, lecture fees, or research
More informationLipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial
Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial Michelle L. O Donoghue, Robert P. Giugliano, Anthony C. Keech, Estella Kanevsky, KyungAh Im, Peter S. Sever, Terje
More informationEvolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors
Evolving Concepts on Lipid Management from Ezetimibe (IMPROVE IT) to PCSK9 Inhibitors Sidney C. Smith, Jr. MD, FACC, FAHA, FESC Professor of Medicine/Cardiology University of North Carolina at Chapel Hill
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationUpdate on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP
Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Professor of Medicine Medical-Director, Preventive Cardiology John Ochsner Heart and Vascular
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationEducational Objectives. Disease Trajectories and CVD Risk Reduction. Hypercholesterolemia Support for LDL-C Causality
Educational Objectives At the conclusion of this activity, participants should be able to: Evaluate the extent of residual CVD risk to which ASCVD patients are exposed, and treat additional CVD risk elements
More informationShould we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP
More informationPCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH
PCSK9 Inhibitors Are They Worth The Money? Michael J. Blaha MD MPH Presented by: Michael J. Blaha November 16, 2017 1 Financial Disclosures Grants: Amgen Foundation, Aetna Foundation Advisory Boards: Amgen,
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationLDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice Nault, Robert P. Giugliano, Anthony C. Keech, Armando
More informationCharacterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER
Characterization of Types and Sizes of Myocardial Infarction Reduced with Evolocumab in FOURIER Stephen D Wiviott, Robert P Giugliano, David A Morrow, Gaetano M De Ferrari, Basil S Lewis, Kurt Huber, Julia
More informationLipid Management 2013 Statin Benefit Groups
Clinical Integration Steering Committee Clinical Integration Chronic Disease Management Work Group Lipid Management 2013 Statin Benefit Groups Approved by Board Chair Signature Name (Please Print) Date
More informationStatins and PCSK9 inhibitors for stroke prevention
Statins and PCSK9 inhibitors for stroke prevention Haralampos Milionis Professor of Internal Medicine School of Medicine, University of Ioannina Ioannina, Greece Reduction in CV events (%) Every 1 mmol/l
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationDoes IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis?
Does IMPROVE-IT & FOURIER Confirm or Refute the LDL Hypothesis? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationBeyond LDL-Cholesterol
Biomarkers for Risk Stratification Beyond LDL-Cholesterol Athanasios J.Manolis Director Cardioilogy Dep, Asklepeion Hospital, Athens, Greece Adj. Professor of Medicine, Emory University Atlanta, USA Adj.
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationManaging Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus
Managing Dyslipidemia and ASCVD Risk: Confusion, Controversy Consensus Pamela B. Morris, MD, FACC, FAHA, FASPC, FNLA Chair, ACC Prevention of Cardiovascular Disease Council and Section The Medical University
More informationAccumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges
ESC 2015 London Accumulating Clinical data on PCSK9 Inhibition: Key Lessons and Challenges Paul M Ridker, MD, MPH Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center for Cardiovascular
More informationRobert A. Vogel, MD Clinical Professor of Medicine University of Colorado Denver
Robert A. Vogel, MD Clinical Professor of Medicine University of Colorado Denver Disclosures: National Coordinator: ODYSSEY Outcomes Study (Phase III Sanofi) Speakers Bureau: Sanofi, Regeneron Case Report
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationInflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
More informationEVIDENCE TO DATE EVOLOCUMAB (REPATHA)
and Clinical Outcomes in Patients with Cardiovascular Disease, March 2017 1 CLINICAL QUESTION In patients with atherosclerotic cardiovascular disease and LDL >1.8mmol/L or non-hdl > 2.6mmol/L, how does
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More information2017 Update in Internal Medicine: Clinical Dyslipidemia Update
2017 Update in Internal Medicine: Clinical Dyslipidemia Update Erin E. Kershaw, M.D. Chief, Division of Endocrinology Associate Professor of Medicine Certified in Endocrinology, Diabetes, and Metabolism
More informationDisclosures. Objectives 2/11/2017
Role of Non-Statin Therapy in CV Risk Reduction James A. Underberg, MD, MS, FACPM, FACP, FASH, FNLA,FASPC Clinical Assistant Professor of Medicine NYU School of Medicine NYU Langone Center for Cardiovascular
More informationConfusion about guidelines: How should we treat lipids?
Confusion about guidelines: How should we treat lipids? Anne Carol Goldberg, MD, FACP, FAHA, FNLA Professor of Medicine Washington University School of Medicine American College of Physicians Missouri
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationTHE CRUCIAL PROBLEM OF ASCVD Can New Therapeutic Options Resolve It? THE CRUCIAL PROBLEM OF ASCVD Can New Therapeutic Options Resolve It?
James A. Underberg, MD, MS, FACPM, FACP, FNYAM, FASPC, FNLA Lipidology and Cardiovascular Disease Prevention Clinical Assistant Professor of Medicine NYU Medical School and NYU Center for CV Prevention
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationThere are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk?
There are many ways to lower triglycerides in humans: Which are the most relevant for pancreatitis and for CV risk? Michael Davidson M.D. FACC, Diplomate of the American Board of Lipidology Professor,
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationCopyright 2017 by Sea Courses Inc.
Diabetes and Lipids Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any means graphic, electronic, or
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationSanjay Kaul, MD, FACC, FAHA Division of Cardiology Cedars-Sinai Medical Center Los Angeles, California
Targeting Inflammation in Atherosclerosis: Has CANTOS Nailed It? Controversies and Advances in the Treatment of Cardiovascular Disease The Seventeenth in the Series Beverly Hills, November 16, 2017 Sanjay
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationInclisiran lowers LDL-C and PCSK9 irrespective of diabetes status without worsening glycemia
ORION-1 Trial Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status without worsening glycemia Lawrence A Leiter, MD, FRCPC, FACP, FACE, FAHA St Michael s Hospital, Toronto 1 Presented on behalf
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationCholesterol, guidelines, targets and new medications
Cholesterol, guidelines, targets and new medications Alexis Baass MD, MSc, FRCPC, DABCL, FNLA Medical Biochemist and Lipidologist MUHC Clinical Researcher and Lipidologist IRCM Disclaimers Grants/Research
More informationLDL and the Benefits of Statin Therapy
LDL and the Benefits of Statin Therapy Allan Sniderman McGill University ACC/AHA did not recommend a target-based approach. Right? P 2899 The Expert Panel was unable to find any RCTs that evaluated titration
More informationLipid Management C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute
Lipid Management 2018 C. Samuel Ledford, MD Interventional Cardiology Chattanooga Heart Institute Disclosures No Financial Disclosures Disclosures I am an Interventional Cardiologist I put STENTS in for
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More information2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice
2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine
More information2/26/19. Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care. Disclosures. Faculty
Secondary Cardiovascular Risk Reduction: Incorporating Evolving Data to Individualize Care Faculty v Karol E. Watson, MD, PhD Professor of Medicine/Cardiology Co-director, UCLA Program in Preventive Cardiology
More informationNew Guidelines in Dyslipidemia Management
The Fourth IAS-OSLA Course on Lipid Metabolism and Cardiovascular Risk Muscat, Oman, February 2018 New Guidelines in Dyslipidemia Management Dr. Khalid Al-Waili, MD, FRCPC, DABCL Senior Consultant Medical
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationCholesterol Medicines New & Old: What to Use When
Cholesterol Medicines New & Old: What to Use When Patrick E. McBride, M.D., M.P.H. Division of Cardiovascular Medicine Preventive Cardiology Program Disclosures McBride no conflicts of interest Outline
More informationLatest Guidelines for Lipid Management
Latest Guidelines for Lipid Management Goals Recognize the differences between different guidelines Understand the effective strategies to tailor lipid lowering therapies based on evidence and guideline
More informationHYPERCHOLESTEROLEMIA
UPDATES ON HYPERCHOLESTEROLEMIA WITH EMPHASIS ON PCSK9 INHIBITORS July, 2018 Chicago by Ernesto L. Chua, MD, FACC, FACP, FPCP Board Certified in Internal Medicine Board Certified in Cardiology COL, USAF,
More informationPreventing coronary artery disease: Cholesterol or inflammation?
Preventing coronary artery disease: Cholesterol or inflammation? Alexis Baass MD, MSc, FRCPC, DABCL, FNLA Medical Biochemist and Lipidologist MUHC Clinical Researcher and Lipidologist IRCM Disclaimers
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationDeep Dive into Contemporary Cholesterol Management. Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City
Deep Dive into Contemporary Cholesterol Management Kim Allan Williams, Sr., MD, FACC Pamela B. Morris, MD, FACC 7 October 2016 Mexico City Introduction: Pamela B. Morris, MD, FACC COMING TO CONSENSUS IN
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationREPATHA (PCSK9 INHIBITORS)
REPATHA (PCSK9 INHIBITS) Indications: PCSK9 Inhibitors are indicated for treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease as
More informationDavid Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon
David Y. Gaitonde, MD, FACP Endocrinology DDEAMC, Fort Gordon I have no actual or potential conflicts of interest in relation to this program or presentation. Raphael School of Athens, 1509-1511 Apply
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationPCSK9 inhibition across a wide spectrum of patients: One size fits all?
PCSK9 inhibition across a wide spectrum of patients: One size fits all? PACE ESC Barcelona 2017 G.K. Hovingh MD PhD MBA dept of vascular medicine Academic Medical Center the Netherlands g.k.hovingh@amc.uva.nl
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationAlirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials
Alirocumab Treatment Effect Did Not Differ Between Patients With and Without Low HDL-C or High Triglyceride Levels in Phase 3 trials G. Kees Hovingh, 1 Richard Ceska, 2 Michael Louie, 3 Pascal Minini,
More informationIs it an era for statin for life?
Is it an era for statin for life? Mohamed Abdel Ghany Professor of Cardiology Cairo University Cardiovascular Disease (CVD) is the leading global cause of death 1 Dyslipidemia as a main Risk Factor for
More informationA Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease.
A Naturally Randomized Trial Comparing the Effect of Genetic Variants that Mimic CETP Inhibitors and Statins on the Risk of Cardiovascular Disease. Brian A. Ference MD, MPhil, MSc, John J. P. Kastelein
More informationWhen Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes
When Statins Aren t Enough: Appropriate Therapies for High-Risk Patients with Diabetes Kim K. Birtcher, MS, PharmD, AACC, FNLA, CLS, BCPS (AQ-Cardiology), CDE Clinical Professor University of Houston College
More informationTHIERS CHAGAS BAHIA FOURIER- ESTUDO DE INIBIÇÃO DA PCSK9 EM PACIENTES DE ALTO RISCO CARDIOVASCULAR
FOURIER- ESTUDO DE INIBIÇÃO DA PCSK9 EM PACIENTES DE ALTO RISCO CARDIOVASCULAR THIERS CHAGAS BAHIA Global Core Content: Do not copy or distribute. Placeholder for Regional/Local Disclaimer. CONFLITO DE
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationImpact of a 1- or 2-dose starting regimen of inclisiran, a novel sirna inhibitor to PCSK9 on time averaged LDL-C reductions over 1 year
ORION-1 Impact of a 1- or 2-dose starting regimen of inclisiran, a novel sirna inhibitor to PCSK9 on time averaged LDL-C reductions over 1 year Kausik K Ray, Ulf Landmesser, Lawrence A Leiter, David Kallend,
More informationManagement of LDL as a Risk Factor. Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil
Management of LDL as a Risk Factor Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Consulting for: Merck, Astra Zeneca, ISIS- Genzyme, Novo-Nordisk, BMS, Pfizer,
More information